- Home
- CX vs MDGL Comparison
CX vs MDGL Comparison
Compare CX & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CX
- MDGL
- Stock Information
- Founded
- CX 1906
- MDGL 2011
- Country
- CX Mexico
- MDGL United States
- Employees
- CX N/A
- MDGL N/A
- Industry
- CX Building Materials
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- CX Industrials
- MDGL Health Care
- Exchange
- CX Nasdaq
- MDGL Nasdaq
- Market Cap
- CX 7.5B
- MDGL 7.1B
- IPO Year
- CX 1999
- MDGL N/A
- Fundamental
- Price
- CX $5.40
- MDGL $301.66
- Analyst Decision
- CX Buy
- MDGL Buy
- Analyst Count
- CX 6
- MDGL 10
- Target Price
- CX $7.53
- MDGL $354.75
- AVG Volume (30 Days)
- CX 19.0M
- MDGL 317.2K
- Earning Date
- CX 04-28-2025
- MDGL 05-06-2025
- Dividend Yield
- CX 1.53%
- MDGL N/A
- EPS Growth
- CX 417.83
- MDGL N/A
- EPS
- CX 0.06
- MDGL N/A
- Revenue
- CX $16,200,000,000.00
- MDGL $180,133,000.00
- Revenue This Year
- CX $7.56
- MDGL $228.41
- Revenue Next Year
- CX $5.63
- MDGL $73.44
- P/E Ratio
- CX $8.04
- MDGL N/A
- Revenue Growth
- CX N/A
- MDGL N/A
- 52 Week Low
- CX $4.89
- MDGL $189.00
- 52 Week High
- CX $8.60
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- CX 45.33
- MDGL 40.18
- Support Level
- CX $5.12
- MDGL $292.49
- Resistance Level
- CX $5.45
- MDGL $330.64
- Average True Range (ATR)
- CX 0.28
- MDGL 20.56
- MACD
- CX 0.01
- MDGL -1.56
- Stochastic Oscillator
- CX 57.95
- MDGL 22.48
About CX Cemex S.A.B. de C.V. Sponsored ADR
Cemex SAB de CV is a ready-mix concrete company that mainly engaged in activities that are oriented to the construction industry, mainly through the production, marketing, sale, and distribution of cement, ready-mix concrete, aggregates, urbanization solutions, and other construction materials and services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.